Credit Suisse Initiates Medpace At Outperform, Says Co. Should Outgrow Industry
Credit Suisse has started coverage of Medpace Holdings Inc (NASDAQ: MEDP) with an Outperform rating, saying the contract research organization should benefit from a strong fundamental backdrop while having a competitive advantage due to its scientifically-driven full-service approach.
The brokerage set a price target of $35, which represents a potential upside of 14 percent over Friday's close.
"It should grow ahead of the industry and more profitably without meaningful capital requirements, supporting double-digit revenue and EPS growth over the long term," analyst Erin Wilson wrote in a note.
While the company conducts clinical trials across all major therapeutic categories, its areas of strength include cardiology, metabolic diseases, oncology, endocrinology, CNS, anti-viral and anti-infective (AVAI). The company generates 85 percent of its revenue from small and mid-size biotech customers.
Wilson sees Medpace's industry-leading revenue growth and superior profit profile (30 percent EBITDA margin vs. peer average of about 20 percent) as sustainable, given strict adherence to its highly cost-efficient, full-service operating model.
Meanwhile, the analyst estimates the overall CRO market at $29 billion, rising 6–8 percent annually, a trajectory Medpace should consistently exceed over the longer term. Wilson projects that 41 percent of clinical development is outsourced, a metric is expected to rise to 50 percent by 2020.
Wilson expects EPS of $1.47 on revenue of $367 million for 2016, and EPS of $1.63 on revenue of $414.6 million for 2017.
At time of writing, shares of Medpace fell 3.85 percent to $29.52.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for MEDP
Date | Firm | Action | From | To |
---|---|---|---|---|
Jul 2021 | Credit Suisse | Maintains | Outperform | |
Mar 2021 | Credit Suisse | Maintains | Outperform | |
Feb 2021 | Truist Securities | Maintains | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Initiation Analyst Ratings